Zoniporide dihydrochloride is a potent and selective inhibitor of the type 1 sodium-hydrogen exchanger (NHE-1), with an IC50 of 14 nM for human NHE-1 and >150-fold selectivity over other NHE isoforms; it effectively inhibits NHE-1-dependent human platelet swelling ex vivo (IC50 = 59 nM); it demonstrates a dose-dependent reduction in infarct size in anesthetized open-chest rabbits (ED50 = 0.45 mg/kg/h) when administered intravenously at 0.25–4 mg/kg every hour for 2 hours.